Interní Med. 2012; 14(11): 432-436

Haemophilia

MUDr.Petr Smejkal, Ph.D.
Oddělení klinické hematologie, FN Brno a Lékařská fakulta Masarykovy univerzity Brno

Hemophilia is a rare hereditary disease with incidence of about 1 patient per 10 000 inhabitants. Caring for these patients is costly and

is most effectively provided by specialized haemophilia centers. However every physician may encounter these patients in an acute

situation or solve their chronic problems.

Keywords: haemophilia, diagnosis, treatment, FVIII inhibitor, guidelines

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Smejkal P. Haemophilia. Interní Med. 2012;14(11):432-436.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Guidelines for the Management of Hemophilia. World Federation of Hemophilia 2005. http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdf
    2. Lee CA, Berntorp E, Hoots WK. Textbook of Hemophilia. 2. vyd. Blackwell Publishing 2010. Go to original source...
    3. O´Shaughnessy D, Makris M, Lillicarp D. Practical Hemostasis and Thrombosis. 1. vyd. Blackwell Publishing 2005. Go to original source...
    4. Bátorová A, Jankovičová D, Žarnovičanová M, et al. Národné štandardné postupy pre liečbu hemofilie a iných vrodených koagulopatií v Slovenskej republike. Lek Obz 2008; 56: 330-340.
    5. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/ FVIII tolerization that avoids immunological ganger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia 2012; 18: e18-e20. Go to original source... Go to PubMed...
    6. Astermark J, Rocino A, von Depka M, et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45. Go to original source... Go to PubMed...
    7. Hay CRM, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors´ Organisation. Br J Haematol 2006; 133: 591-605. Go to original source... Go to PubMed...
    8. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl. 1): 1-22. Go to original source... Go to PubMed...
    9. Colvin BT, Astermark J, Fischer K, et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-374. Go to original source... Go to PubMed...
    10. Český národní hemofilický program. http://cnhp.registry.cz

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.